179 related articles for article (PubMed ID: 7576955)
1. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
Ambros PF; Ambros IM; Strehl S; Bauer S; Luegmayr A; Kovar H; Ladenstein R; Fink FM; Horcher E; Printz G
Eur J Cancer; 1995; 31A(4):510-5. PubMed ID: 7576955
[TBL] [Abstract][Full Text] [Related]
2. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
[TBL] [Abstract][Full Text] [Related]
3. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
4. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma: a multiple biological disease.
Tonini GP
Eur J Cancer; 1993; 29A(6):802-4. PubMed ID: 8484968
[TBL] [Abstract][Full Text] [Related]
6. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
7. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
[TBL] [Abstract][Full Text] [Related]
10. Morphologic and molecular cytogenetics in neuroblastoma.
Avet-Loiseau H; Venuat AM; Benard J; Leibovitch MP; Hartmann O; Bernheim A
Cancer; 1995 Apr; 75(7):1694-9. PubMed ID: 8826929
[TBL] [Abstract][Full Text] [Related]
11. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.
Lavarino C; Cheung NK; Garcia I; Domenech G; de Torres C; Alaminos M; Rios J; Gerald WL; Kushner B; LaQuaglia M; Mora J
BMC Cancer; 2009 Feb; 9():44. PubMed ID: 19192278
[TBL] [Abstract][Full Text] [Related]
12. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
13. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
15. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridisation on tumour imprints and bone marrow smears. United Kingdom Children's Cancer Study Group.
Taylor CP; McGuckin AG; Bown NP; Reid MM; Malcolm AJ; Pearson AD; Sheer D
Br J Cancer; 1994 Mar; 69(3):445-51. PubMed ID: 8123471
[TBL] [Abstract][Full Text] [Related]
17. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
18. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma. Effect of genetic factors on prognosis and treatment.
Brodeur GM; Azar C; Brother M; Hiemstra J; Kaufman B; Marshall H; Moley J; Nakagawara A; Saylors R; Scavarda N
Cancer; 1992 Sep; 70(6 Suppl):1685-94. PubMed ID: 1325279
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
